Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting

Gregory L. Pricea Eli Lilly and Company, Indianapolis, IN, USA

Lavanya Sudharshanb McKesson Life Sciences, The Woodlands, TX, USA

Paula Ryanc Texas Oncology – The Woodlands, The Woodlands, TX, USA

Jonathan Rajkumarb McKesson Life Sciences, The Woodlands, TX, USA

Kristin M. Sheffielda Eli Lilly and Company, Indianapolis, IN, USA

Emily Nash Smytha Eli Lilly and Company, Indianapolis, IN, USA

Claudia Morato Guimaraesa Eli Lilly and Company, Indianapolis, IN, USA

Sarah Rybowskia Eli Lilly and Company, Indianapolis, IN, USA

Gebra Cuyun Cartera Eli Lilly and Company, Indianapolis, IN, USA

Wambui Grace Gathirua-Mwangia Eli Lilly and Company, Indianapolis, IN, USA

Yu-Jing Huanga Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]

Your download is now in progress and you may close this window